Abstract
Although adjuvant imatinib (IM) for high risk GIST is an accepted treatment consideration, the duration of therapy remains controversial. The recently published SSGXVIII/AIO randomized clinical trial of 3 years vs. 1 year of adjuvant IM has established a benefit of RFS and OS for the 3 year cohort. Future studies are necessary to continue to further delineate risk variables for GIST recurrence.
MeSH terms
-
Antineoplastic Agents / administration & dosage*
-
Benzamides
-
Chemotherapy, Adjuvant / methods*
-
Clinical Trials, Phase III as Topic*
-
Gastrointestinal Stromal Tumors / drug therapy*
-
Gastrointestinal Stromal Tumors / mortality
-
Humans
-
Imatinib Mesylate
-
Piperazines / administration & dosage*
-
Practice Guidelines as Topic*
-
Pyrimidines / administration & dosage*
-
Randomized Controlled Trials as Topic*
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate